epoetin alfa
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Blood Transfusion
Conditions
Blood Transfusion, Blood Transfusion, Autologous, Orthopedic Procedures, Orthopedic Surgery, Cardiovascular Surgical Procedure
Trial Timeline
Jan 1, 1990 → May 1, 1992
NCT ID
NCT00270075About epoetin alfa
epoetin alfa is a phase 2/3 stage product being developed by Johnson & Johnson for Blood Transfusion. The current trial status is completed. This product is registered under clinical trial identifier NCT00270075. Target conditions include Blood Transfusion, Blood Transfusion, Autologous, Orthopedic Procedures.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00270010 | Phase 2 | Completed |
| NCT00266617 | Phase 2 | Completed |
| NCT00002022 | Pre-clinical | Completed |
| NCT00269984 | Phase 2 | Completed |
| NCT00269945 | Phase 2 | Completed |
| NCT00270114 | Phase 2/3 | Completed |
| NCT00446602 | Phase 2 | Withdrawn |
| NCT00270179 | Phase 3 | Completed |
| NCT00269997 | Phase 2 | Completed |
| NCT00270023 | Phase 2/3 | Completed |
| NCT00270270 | Phase 2 | Completed |
| NCT00337935 | Phase 2 | Completed |
| NCT00306267 | Phase 2 | Terminated |
| NCT00641589 | Phase 1 | Completed |
| NCT00246298 | Phase 2 | Terminated |
| NCT00212875 | Phase 2 | Completed |
| NCT00236405 | Phase 2 | Terminated |
| NCT00240734 | Phase 2 | Terminated |
| NCT00210587 | Phase 3 | Completed |
| NCT00236678 | Phase 2 | Terminated |
Competing Products
20 competing products in Blood Transfusion
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| micafungin + voriconazole | Astellas Pharma | Approved | 85 |
| Cefiderocol | Shionogi | Phase 2 | 52 |
| Bunazosin + Doxazosin + Valsartin | Eisai | Approved | 85 |
| Pegfilgrastim | Kyowa Kirin | Phase 2 | 52 |
| epoetin alfa | Johnson & Johnson | Phase 2/3 | 65 |
| epoetin alfa | Johnson & Johnson | Phase 2 | 52 |
| Metoprolol Succinate + Hydrochlorothiazide | AstraZeneca | Phase 3 | 77 |
| AZD6140 + Placebo | AstraZeneca | Phase 1 | 33 |
| NKTR-118 + moxifloxacin + Placebo | AstraZeneca | Phase 1 | 33 |
| MEDI-551 | AstraZeneca | Phase 1 | 33 |
| Ecallantide + Cyklokapron(R) | Merck | Phase 2 | 52 |
| Daptomycin | Merck | Phase 2 | 52 |
| ecallantide + placebo | Merck | Phase 2 | 52 |
| MK0859 | Merck | Phase 1 | 33 |
| Ecallantide + Placebo | Merck | Phase 2 | 52 |
| HSC835 | Novartis | Phase 2 | 52 |
| Aliskiren | Novartis | Approved | 85 |
| Aliskiren and HCTZ | Novartis | Approved | 85 |
| Aliskiren + Amlodipine + Placebo Aliskiren + Placebo Amlodipine | Novartis | Phase 2 | 52 |
| Darbepoetin alfa | Amgen | Phase 1/2 | 40 |